Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Cholangiocarcinoma Market, By Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, and 5 fluorouracil (5-FU)), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), Ivosidenib (Phase 3)), Immunotherapy, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 185.4 Mn in 2021 and is expected to exhibit a CAGR of 12.8% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Rising research and development activities by pharmaceutical companies are expected to propel growth of the global cholangiocarcinoma market over the forecast period. For instance, in September 2019, Merck Sharp & Dohme Corp, a pharmaceutical company, initiated the investigational clinical trial study on Pembrolizumab (immunotherapy) in combination with Gemcitabine/Cisplatin for the treatment of cholangiocarcinoma. The study is currently in Phase 3 clinical trials and is expected to be completed by August 2023.

Global Cholangiocarcinoma Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has drastically affected the conductance clinical trials. Many trials have paused enrollment of participants and researchers are also facing multiple challenges associated with setting up remote visits and performing laboratory and other study assessments. According to a survey conducted by Medidata Solutions, Inc. (an American technology company, which develops and markets software for clinical trials), on April 23, 2020, 63% of survey respondents reported that Pharmaceutical companies which were conducting clinical trials stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies. Even, the U.S. Food and Drug Administration (FDA) released guidelines on conducting clinical trials of medical products during the COVID-19 public health emergency in March 2020, which were further updated on July 02, 2020. The guidelines included general considerations to assist sponsors and researchers, which ensures the safety of trial participants, and is in compliance with good clinical practice (GCP) for the duration of the COVID-19 public health emergency.

Browse 27 Market Data Tables and 31 Figures spread through 156 Pages and in-depth TOC on “Global Cholangiocarcinoma Market”-  Forecast to 2028, Global Cholangiocarcinoma Market, By Treatment Type (Chemotherapy [Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, and 5 fluorouracil (5-FU) ], Targeted Therapy, (Pemigatinib, Infigratinib (Phase 3), and Ivosidenib (Phase 3), Immunotherapy, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

https://www.coherentmarketinsights.com/market-insight/cholangiocarcinoma-market-4435

Moreover, increasing prevalence of cholangiocarcinoma is also expected to aid in growth of the Global Cholangiocarcinoma Market over the forecast period. For instance, according to World Cholangiocarcinoma Day Statistics in 2016, in May 2019, the incidence and mortality rates of cholangiocarcinoma in England were presented at the ESMO-GI2 conference in Barcelona, which showed that both incidence and mortality rates had been steadily increasing in England over the past 17 years (2001 – 2017). If this increase continues, then by 2030, cholangiocarcinoma will no longer be a rare cancer.

Key Takeaways of the Global Cholangiocarcinoma Market:

  • The global cholangiocarcinoma market is expected to exhibit a CAGR of 12.8% during the forecast period due to rising research and development activities by pharmaceutical companies, which is expected to boost growth of the market. For instance, in 2015, Leap therapeutics, operates as a clinical-stage biopharmaceutical company, developed a humanized monoclonal antibody DKN-01 for the treatment of bile duct cancer through its anti-neoplastic activity, the study is currently under clinical trial phase I.
  • Among treatment type, chemotherapy segment accounted for the largest market share in global cholangiocarcinoma market in 2021. For instance, in August 2020, RenovoRx, a medical device company, announced that it received Orphan Drug Designation by the U.S. Food Drug and Administration for RenovoCath, a novel intra-arterial device of Gemcitabine (Gemzar), for the treatment of patients with cholangiocarcinoma (CCA).
  • On the basis of distribution channel, hospital pharmacies segment is estimated to hold a dominant position in the global cholangiocarcinoma market over the forecast period. Moreover, the rise in hospital admission of patients suffering from intrahepatic cholangiocarcinoma, is expected to favor growth of the hospital pharmacies segment over the forecast period. For instance, according to the report published by National Organization for Rare Disorders in 2020, the incidence of intrahepatic cholangiocarcinoma in the U.S. is approximately 0.7 per 100,000.
  • Among the regions, North America accounted for the largest market share in global cholangiocarcinoma market in 2021. The U.S. is expected to be the most lucrative market for oral biologics, owing to the increasing prevalence of Cholangiocarcinoma. For instance, according to the American Society of Clinical Oncology (ASCO)’s report in 2019, approximately 8,000 people in the U.S. were diagnosed with bile duct cancer in 2019.
  • Major players operating in the global cholangiocarcinoma market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner